Here you can find the latest news and information about our company and products, browse our latest press releases, and download imagery and factsheets for your use.
Lyon, France- June 29, 2015- MSD, known as Merck in the United States and Canada (NYSE: MRK) and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), the two partner companies in Sanofi Pasteur MSD, announce today the appointment of David Khougazian as president of Sanofi Pasteur MSD.
On July 1, Khougazian will join Sanofi Pasteur MSD and effective September 1, will succeed Dr. Jean-Paul Kress, who led the company since July 2011. Kress will leave Sanofi Pasteur MSD to join the Sanofi group.
“Sanofi Pasteur MSD is a major player in the European vaccine market. Under Jean-Paul’s tenure, the company launched Hexyon and Zostavax and prepared the arrival of two major new products which will fuel our joint-venture’s growth. David’s appointment marks a new phase in our development in Western Europe, a challenging and strategic region for our vaccines activity,” said Olivier Charmeil, president and CEO of Sanofi Pasteur. “His knowledge of European markets and external stakeholders will be strong assets to grow Sanofi Pasteur MSD’s positions in Europe.”
“David’s leadership skills and expertise in global strategy and health policy make him uniquely suited to lead Sanofi Pasteur MSD in Europe,” commented Jacques Cholat, president, Merck Vaccines. “His experience will help us deliver important vaccines to improve the health of European populations.”
Totally dedicated to vaccine and Europe, Sanofi Pasteur MSD combines the innovation capabilities from two major global leaders to the benefit of its customers and offers the broadest range of vaccines. Among others, the company is the European leader for flu vaccines and has brought innovative vaccines to Europe: Gardasil, the first vaccines to help prevent human papillomavirus (HPV) diseases, including cervical cancer, Hexyon, the only fully liquid hexavalent pediatric combination vaccine available in the market, as well as Zostavax, a vaccine to help prevent Shingles in elderly people.
David Khougazian’s biography
A French citizen, David Khougazian is an engineer graduated from the ENSAE, the national aeronautical and space engineering school, and holds an MBA from the Collège des Ingénieurs. Prior to his appointment, David Khougazian served as Sanofi CEO Chief of Staff. In this position since 2011, he worked closely supporting the CEO and the Sanofi Executive Committee in transforming the company and delivering on its development agenda. As part of his role, he assumed responsibility for various global strategic and organizational projects, supported the post-acquisition integration of Genzyme Inc., led the global health policy effort and managed interactions with multiple external stakeholders. Former positions include various business operations’ positions in sales and marketing and as General Manager. David joined Rhône-Poulenc in 1997 where he held several positions in Finance and Corporate Development and participated in the creation of Aventis, a combination with Hoechst AG. He also served as Vice President Mergers & Acquisitions for Aventis. David started his career in 1992 at CCF, the fourth largest French bank.
# # #
About Sanofi Pasteur MSD
Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the distribution of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.
For more information, visit www.spmsd.com
- END -
FleishmanHillard – Marion Cocherel
+33 6 88 56 85 38 – email@example.com
Sanofi Pasteur MSD – Andrea Rappagliosi
Sanofi Pasteur MSD awarded recognition by the Great Place to Work organization in Italy & Spain
Lyon, May 27th, 2015 – Sanofi Pasteur MSD is delighted to share the news that the company has been recognized by the Great Place to Work Organization amongst the best places to work in Italy and Spain in 2015.
Great Place to Work is an international institute which publishes an annual list of the best places to work based on a Trust Index survey performed amongst company employees and through analysis of a company culture audit.
Sanofi Pasteur MSD Italy reaches No.1 in the Great Place to Work 2015 ranking.
“This recognition received in the year of our 20th anniversary is the result of our dedication and talent. It confirms that Sanofi Pasteur MSD is investing on the most important resource: people. This award differentiates the company and its values vs our competitors and it will be a tremendous booster for our organization too. I take this opportunity to sincerely thank all employees of Sanofi Pasteur MSD Italy for the winning company that we are building together”, says Nicoletta Luppi, Vice President of Sanofi Pasteur MSD in Italy.
This award is the result of the Trust Index survey performed amongst SPMSD employees to measure trust in the Company management, pride for their job, loyalty for the Company and of a thorough analysis performed by the Great Place to Work Institute on the company culture audit.
For the second consecutive year, Sanofi Pasteur MSD Spain has also achieved a Great Place to Work certification in the 50-100 employees category, based on the commitment and trust of its employees in the company, as well as its excellent practices in human resources management.
Ricardo Brage, General Manager of Sanofi Pasteur MSD in Spain has said: “We are proud to continue being recognized as one of the top 50 companies to work for in Spain, as well as for having improved our results and position within our category and sector”.
Of the 8 companies listed in the 50-100 employees category in Spain, the Sanofi Pasteur MSD has reached the fifth position. With a response rate of 95% of employees, the results of the survey on corporate culture show strong pride in belonging (90%), trust in the management team and their leadership (76%) as well as a friendly atmosphere (82%).
For more information on the Great Place to Work organization, visit www.greatplacetowork.com
# # #
For further information please contact:
Sanofi Pasteur MSD Corporate Sylvia Martin-Jarrand Tel : +33 4 37 28 40 55 firstname.lastname@example.org
Luxembourg, April 30th, 2015 – Vaccines Europe launch a call on the European Commission and Member States to align and streamline communications activities around the seasonal influenza vaccination campaigns by setting a European Influenza Day to launch seasonal vaccination every year.
Vaccines Europe President Andrea Rappagliosi prompts the establishment of a common EU-wide day to launch the seasonal influenza vaccination
campaigns across all Member States in occasion of the DG SANTÉ High-Level Hearing on Seasonal Influenza Vaccination.
The meeting, organised by the European Commission back-to-back to the Workshop on joint procurement being held in Luxembourg on 29-30 April 2015, is bringing together key stakeholders across public health, regulatory, industry and civil society to discuss concrete measures that can increase flu vaccination rates in the EU.
Andrea Rappagliosi said that “the establishment of a common date to kick-off the Member States communication campaigns with a single voice and in an aligned manner will significantly raise awareness on the needs and means to keep populations properly immunised against flu”.
Communications on the benefits of flu vaccination came on the spotlight as one of the crucial factors that must be properly addressed at EU level to help achieving the necessary coverage targets, according to the Commission Staff Working Document following up on the implementation of 2009 Council Recommendation on Seasonal Influenza Vaccination.
Seasonal flu epidemics still represent an underestimated cause of significant morbidity and mortality in the EU; ECDC estimates up to 40,000 premature deaths on an average influenza season. Despite recommendations for vaccination being in place across most EU countries, the gap with actual implementation stays large with only two EU Member States reaching the
Council Recommendation’s 75% target. Political leadership remains key to addressing the status quo.
About Vaccines Europe
Vaccines Europe is the specialised vaccine group operating within the
European Federation of Pharmaceutical Industries and Associations (EFPIA).
It represents the major research-based vaccine companies as well as small
and medium-sized enterprises operating in Europe.
For more information on Vaccines Europe, visit www.vaccineseurope.eu
For more information on EFPIA, visit www.efpia.eu
Any media queries can be addressed to
Magdalena R. de Azero
Executive Director, Vaccines Europe